Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.

Margherita RiminiChanghoon YooSara LonardiGianluca MasiAlessandro GranitoYeonghak BangMario Domenico RizzatoCaterina VivaldiLuca IelasiHyung-Don KimFrancesca BergamoFrancesca SalaniSimona LeoniBaek-Yeol RyooMin-Hee RyooValentina BurgioStefano CascinuAndrea Casadei-Gardini

Published in: Targeted oncology (2021)

The REP index is an independent prognostic factor for OS and PFS in patients with advanced HCC treated with regorafenib.

Keyphrases

prognostic factors
metastatic colorectal cancer
combination therapy
newly diagnosed
replacement therapy